Denali Therapeutics (DNLI) Income from Continuing Operations (2017 - 2026)
Denali Therapeutics (DNLI) reported Income from Continuing Operations of 128447000.0 for Q1 2026, up 3.4% year-over-year from 124221579.21 in Q1 2025, and little changed on a QoQ basis from 128447000.0 in Q4 2025.
Denali Therapeutics (DNLI) has 10 years of Income from Continuing Operations data on file, last reported at 128447000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 3.4% year-over-year to 128447000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 507915000.0 (down 11.91% YoY) and the FY2025 annual result came in at 512540000.0, down 21.23% from the prior year.
- Income from Continuing Operations steadied at 128447000.0 in Q1 2026 per DNLI's latest filing, from 128447000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 183383000.0 in Q2 2023 and bottomed at 132970000.0 in Q1 2025.
- The 5-year median for Income from Continuing Operations is 107192000.0 (2024), against an average of 90357823.53.
- The widest annual swing landed in 2023, when Income from Continuing Operations surged 411.91%; it then sank 154.0% in 2024.
- Tracing DNLI's Income from Continuing Operations over 5 years: stood at 98678000.0 in 2022, then retreated by 21.07% to 119473000.0 in 2023, then grew by 4.01% to 114685000.0 in 2024, then dropped by 12.0% to 128447000.0 in 2025, then changed by 0.0% to 128447000.0 in 2026.
- Per Business Quant, the three latest DNLI Income from Continuing Operations figures stand at 128447000.0 (Q1 2026), 128447000.0 (Q4 2025), and 126902000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Denali Therapeutics | 3.82 Bn | 3.82 Bn | - | -128.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -128.45 Mn |
| Dec 31, 2025 | -128.45 Mn |
| Sep 30, 2025 | -126.90 Mn |
| Jun 30, 2025 | -124.12 Mn |
| Mar 31, 2025 | -132.97 Mn |
| Dec 31, 2024 | -114.69 Mn |
| Sep 30, 2024 | -107.19 Mn |
| Jun 30, 2024 | -99.03 Mn |
| Mar 31, 2024 | -101.80 Mn |
| Dec 31, 2023 | -119.47 Mn |
| Sep 30, 2023 | -99.35 Mn |
| Jun 30, 2023 | 183.38 Mn |
| Mar 31, 2023 | -109.78 Mn |
| Dec 31, 2022 | -98.68 Mn |
| Sep 30, 2022 | -103.30 Mn |
| Jun 30, 2022 | -58.79 Mn |
| Mar 31, 2022 | -66.50 Mn |
| Dec 31, 2021 | -75.26 Mn |
| Sep 30, 2021 | -84.59 Mn |
| Jun 30, 2021 | -60.69 Mn |
| Mar 31, 2021 | -70.04 Mn |
| Dec 31, 2020 | 244.89 Mn |
| Sep 30, 2020 | -58.23 Mn |
| Jun 30, 2020 | -58.76 Mn |
| Mar 31, 2020 | -56.76 Mn |
| Dec 31, 2019 | -57.76 Mn |
| Sep 30, 2019 | -46.26 Mn |
| Jun 30, 2019 | -58.34 Mn |
| Mar 31, 2019 | -38.99 Mn |
| Dec 31, 2018 | 77.53 Mn |
| Sep 30, 2018 | -35.37 Mn |
| Jun 30, 2018 | -54.72 Mn |
| Mar 31, 2018 | -25.75 Mn |
| Dec 31, 2017 | -23.54 Mn |
| Sep 30, 2017 | -22.29 Mn |
| Jun 30, 2017 | -22.57 Mn |
| Mar 31, 2017 | -21.74 Mn |